3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Neoplasm Metastasis
3
Stomatitis
2
Stomach Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Trauma, Nervous System
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Lipoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Intracranial Hemorrhages
1
Interventions
Carboplatin
71
Etoposide
63
Topotecan
42
Cisplatin
38
pembrolizumab
30
atezolizumab
26
durvalumab
22
Paclitaxel
16
Nivolumab
14
PM 01183
13
rovalpituzumab tesirine
11
Pemetrexed
11
amrubicin
9
Ipilimumab
9
Injections
9
Irinotecan
8
AMG 757
8
trilaciclib
7
etoposide phosphate
6
EC regimen
6
Drug Therapy
6
Docetaxel
6
Bevacizumab
6
tremelimumab
5
MLN 8237
5
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
olaparib
4
chiauranib
4
budigalimab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Small Cell Lung Carcinoma
×
Saline Solution
×
Clear all
NCT03066778
2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3
Completed
453 enrolled
23 charts